CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性套细胞淋巴瘤的管理
英文原题：Management of relapsed/refractory mantle cell lymphoma.
查看英文原题
Management of relapsed/refractory mantle cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
本文综述当前关于复发/难治性套细胞淋巴瘤（MCL）患者管理的证据，并概述过去二十年开发的多种新型疗法。我们还介绍新疗法问世后总体缓解率、完全缓解率、缓解持续时间和预期寿命如何显著改善，尤其是共价布鲁顿酪氨酸激酶抑制剂（BTKi）和CAR-T 细胞疗法的引入。BTKi或CAR-T 治疗后疾病进展患者可选择的最新疗法，包括非共价BTKi、抗体药物偶联物、BCL-2抑制剂和双特异性抗体，可能进一步改善缓解率和结局。未来研究应聚焦于确定日益丰富治疗选择的最佳序贯和/或联合方案，同时优先考虑具有治愈潜力的策略。
展开英文摘要原文
In this review we summarize the current evidence describing the management of patients with relapsed/refractory MCL and outline the various novel therapeutics that have been developed over the past two decades.
We also describe how overall response rates, complete response rates, duration of responses, and life expectancy have dramatically increased with the introduction of novel therapies, particularly covalent Bruton Tyrosine Kinase inhibitors (BTKi) and chimeric antigen receptor T-cell (CAR-T) therapy.
The most recent emerging options for patients with progressive disease following BTKi or CAR-T, including non-covalent BTKi, antibody-drug conjugates, Bcl-2 inhibitors, and bispecific antibodies, may further improve response rates and outcomes. Future directions should focus on identifying the best sequencing and/or combinations of the increasingly available treatment options while prioritizing strategies with curative potential.
论文信息
- 作者
- Alzahrani M、Villa D
- 第一作者单位
- Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.Saudi Arabia
- 通讯作者单位
- Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.Canada
- 文献类型
- 综述
- 期刊
- Leukemia & lymphoma2024 Aug
- 原文标识
- PubMed 38635491 · DOI 10.1080/10428194.2024.2338851